



REPUBLIC OF THE PHILIPPINES  
**INTER-AGENCY TASK FORCE**  
FOR THE MANAGEMENT OF EMERGING INFECTIOUS DISEASES

**RESOLUTION NO. 39**

Series of 2020

May 22, 2020

**WHEREAS**, on 30 April 2020, the President issued Executive Order No. 112, Imposing an Enhanced Community Quarantine in High-Risk Geographic Areas of the Philippines and a General Community Quarantine in the Rest of The Country from 01 To 15 May 2020, Adopting The Omnibus Guidelines On The Implementation Thereof, And For Other Purposes;

**WHEREAS**, on 11 May 2020, the IATF convened to analyze current scientific data and apply the parameters to determine the appropriate community quarantine or social distancing measures that should be implemented in different provinces, highly-urbanized cities (HUCs), and independent component cities (ICCs) in the country.

**WHEREAS**, as of 22 May 2020, there are thirteen thousand five hundred ninety-seven (13,597) confirmed cases of COVID-19 in the Philippines.

**NOW, THEREFORE, BE IT RESOLVED**, as it is hereby resolved, that the IATF approves the following:

- A. The Chairperson and the Co-chairperson are hereby authorized to sign for and on behalf of the Resolutions approved by the Inter-Agency Task Force during regular and special meetings duly convened. Therefore, all previous IATF Resolutions signed for and on behalf of the IATF is hereby confirmed and ratified;
- B. The recommendations of the Department of Science and Technology (DOST) on the participation of the Philippines in the clinical trials for COVID-19 vaccines are hereby approved, the details of which are as follows:
  - a. The collaborating organizations include:
    - i. Adimmune Corporation;
    - ii. Academia Sinica;
    - iii. Chinese Academy of Science - Guangzhou Institute of Biomedicine and Health; and
    - iv. SinoPharma - Wuhan Institute of Biological Products and Beijing Institute.
  - b. The collaborating organizations will be provided with a) the World Health Organization requirements for COVID-19 Vaccine Target Product Profiles; b) Pre-Qualification Process for WHO Approvals; and c) the Philippine Food and Drug Administration (FDA) updated guidelines on Clinical Trials. Pursuant to the foregoing, the FDA is directed to advise on the process to facilitate the issuance of permit for the conduct of the clinical trial in the Philippines.



## RESOLUTION NO. 39

Series of 2020


May 22, 2020


- c. The study sites will be identified together with the researchers that will be involved in the clinical trials; and
- d. Once clinical trials are finished, these will form part of the requirements for the vaccine registration process by the FDA for issuance of the Certificate of Product Registration (CPR) for market release in the Philippines.

A sub-Technical Working Group chaired by the DOST and whose membership shall likewise be determined by the chair, is hereby formed and directed to coordinate with the Department of Health, FDA, Research Institute of Tropical Medicine, and the World Health Organization for matters relating to such clinical trials.

- C. The IATF supports the plans of the DOST on the establishment of the following research centers that can initiate and strengthen local vaccine development towards the country's vaccine self-reliance and self-sufficiency:
  - a. The establishment of the Virology S&T Institute in New Clark City; and
  - b. The reactivation of the Pharmaceutical Development Unit at DOST-ITDI (Industrial Technology Development Institute) as a *Tuklas Lunas* Center for Pharmaceuticals Development.

**APPROVED** during the 39th Inter-Agency Task Force Meeting, as reflected in the minutes of the meeting, held this 22nd of May, 2020 *via* video conference.

  
**FRANCISCO T. DUQUE III**  
Secretary, Department of Health  
IATF Chairperson

  
**KARLO ALEXEI B. NOGRALES**  
Cabinet Secretary, Office of the Cabinet Secretariat  
IATF Co-Chairperson




## CERTIFICATION

This is to certify that:

1. I am presently an Assistant Secretary of the Department of Health;
2. I am the designated Head of the Secretariat of the Inter-Agency Task Force (IATF) on the Management of Emerging Infectious Diseases created under Executive Order No. 168, series of 2014 and chaired by the Department of Health (DOH);
3. The IATF Secretariat holds office in the DOH Main Office, San Lazaro Compound, Tayuman, Sta. Cruz, Manila;
4. I am the custodian of the records of the IATF, including the Minutes of Meetings and Resolutions;
5. In the Regular Meeting of the IATF held on May 22, 2020 via teleconference during which a quorum was present and acted throughout, IATF Resolution No. 39 was unanimously approved and adopted;
6. The foregoing resolution has been signed by Secretary Francisco T. Duque III and Cabinet Secretary Karlo Alexei B. Nograles upon authority duly vested by the IATF Members pursuant to IATF Resolution No. 39;
7. The aforesaid resolution not been altered, modified nor revoked and the same is now in full force and effect;
8. I am executing this Certification for whatever legitimate purpose this may serve.

IN WITNESS WHEREOF, I have hereunto affixed my signature this \_\_\_\_ day of May 2020, Manila.

  
**KENNETH G. RONQUILLO, MD, MPH**  
Assistant Secretary, Department of Health  
Secretariat Head, IATF